Cargando…

Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate

BACKGROUND: Dendritic cells (DCs) are the most potent antigen-presenting cell population for activating tumor-specific T cells. Due to the wide range of methods for generating DCs, there is no common protocol or defined set of criteria to validate the immunogenicity and function of DC vaccines. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiang, Cheryl L-L, Maier, Dawn A, Kandalaft, Lana E, Brennan, Andrea L, Lanitis, Evripidis, Ye, Qunrui, Levine, Bruce L, Czerniecki, Brian J, Powell Jr, Daniel J, Coukos, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283529/ https://www.ncbi.nlm.nih.gov/pubmed/22082029 http://dx.doi.org/10.1186/1479-5876-9-198

Ejemplares similares

Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2011)

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
por: Kandalaft, Lana E., et al.
Publicado: (2013)

Targeting the tumor vasculature to enhance T cell activity
por: Lanitis, Evripidis, et al.
Publicado: (2015)

A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2018)

Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2019)

Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
por: Sarivalasis, Apostolos, et al.
Publicado: (2019)

Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine
por: Boudousquié, Caroline, et al.
Publicado: (2020)

Whole Tumor Antigen Vaccines: Where Are We?
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2015)

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2012)

Primary Human Ovarian Epithelial Cancer Cells Broadly Express HER2 at Immunologically-Detectable Levels
por: Lanitis, Evripidis, et al.
Publicado: (2012)

Immunotherapy of Malignant Melanoma with Tumor Lysate-Pulsed Autologous Monocyte-Derived Dendritic Cells
por: Kim, Dae Suk, et al.
Publicado: (2011)

Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes
por: Ye, Qunrui, et al.
Publicado: (2011)

Quality of tumor lysates used for pulsing dendritic cells is influenced by the method used to harvest adherent tumor cells
por: Herzog, Gloria Isabelle, et al.
Publicado: (2011)

Clinical translation section: accelerating the pace from bench to bedside
por: Kandalaft, Lana E, et al.
Publicado: (2011)

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma
por: Ribas, Antoni, et al.
Publicado: (2010)

Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression
por: Lanitis, Evripidis, et al.
Publicado: (2020)

Mesenchymal Stromal Stem Cell-Derived Microvesicles Enhance Tumor Lysate Pulsed Dendritic Cell Stimulated Autologous T lymphocyte Cytotoxicity
por: Kukia, Nasim Rahmani, et al.
Publicado: (2018)

Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro
por: Dhandapani, Hemavathi, et al.
Publicado: (2021)

Identification of Pancreatic Cancer-Associated Tumor Antigen from HSP-Enriched Tumor Lysate-Pulsed Human Dendritic Cells
por: Kim, Han-Soo, et al.
Publicado: (2014)

Correction to: CART cells are prone to Fas- and DR5-mediated cell death
por: Tschumi, Benjamin O., et al.
Publicado: (2018)

Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity
por: Fritah, Hajer, et al.
Publicado: (2023)

Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Gastric and Colorectal Cancer Patients
por: Gao, Daiqing, et al.
Publicado: (2014)

Dendritic cells pulsed with generated tumor cell lysate from Phyllanthus amarus Schum. & Thonn. induces anti-tumor immune response
por: Mohamed, Shimaa Ibrahim Abdelmenym, et al.
Publicado: (2018)

Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells
por: Benencia, Fabian, et al.
Publicado: (2008)

VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding
por: Lanitis, Evripidis, et al.
Publicado: (2021)

IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
por: Mookerjee, Ananda, et al.
Publicado: (2019)

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012)

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells
por: Irving, Melita, et al.
Publicado: (2021)

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
por: Bol, Kalijn F., et al.
Publicado: (2019)

Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results
por: Mastelic-Gavillet, Beatris, et al.
Publicado: (2019)

Finding a needle in a haystack: Activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients
por: Ye, Qunrui, et al.
Publicado: (2013)

Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy
por: Rainone, Veronica, et al.
Publicado: (2016)

Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
por: Santin, A D, et al.
Publicado: (2002)

miR-155 Overexpression in OT-1 CD8(+) T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen
por: Monnot, Gwennaëlle C., et al.
Publicado: (2019)

Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival
por: Karapetsas, Athanasios, et al.
Publicado: (2015)

Capability of Human Dendritic Cells Pulsed with Autologous Induced Pluripotent Stem Cell Lysate to Induce Cytotoxic T Lymphocytes against HLA-A33-Matched Cancer Cells
por: Nakazawa, Tsutomu, et al.
Publicado: (2022)

Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
por: Benitez-Ribas, Daniel, et al.
Publicado: (2018)

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
por: Yamanaka, R, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_lqs6sthvgneqp1cgcts1ip7li0